These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 17960553)

  • 1. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
    Quik M; Cox H; Parameswaran N; O'Leary K; Langston JW; Di Monte D
    Ann Neurol; 2007 Dec; 62(6):588-96. PubMed ID: 17960553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
    Zhang D; McGregor M; Bordia T; Perez XA; McIntosh JM; Decker MW; Quik M
    Mov Disord; 2015 Dec; 30(14):1901-1911. PubMed ID: 26573698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Mov Disord; 2006 Jan; 21(1):9-17. PubMed ID: 16127720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
    Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
    Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Fox SH; Henry B; Hill M; Crossman A; Brotchie J
    Mov Disord; 2002 Nov; 17(6):1180-7. PubMed ID: 12465055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.
    Quik M; Parameswaran N; McCallum SE; Bordia T; Bao S; McCormack A; Kim A; Tyndale RF; Langston JW; Di Monte DA
    J Neurochem; 2006 Sep; 98(6):1866-75. PubMed ID: 16882311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G; Morissette M; Parent M; Di Paolo T
    Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa.
    Togasaki DM; Protell P; Tan LC; Langston JW; Di Monte DA; Quik M
    Neuropharmacology; 2005 Mar; 48(3):398-405. PubMed ID: 15721172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
    Papa SM; Chase TN
    Ann Neurol; 1996 May; 39(5):574-8. PubMed ID: 8619541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating levodopa-induced dyskinesias in the parkinsonian primate.
    Langston JW; Quik M; Petzinger G; Jakowec M; Di Monte DA
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S79-89. PubMed ID: 10762135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
    Quik M; Mallela A; Ly J; Zhang D
    Mov Disord; 2013 Sep; 28(10):1398-406. PubMed ID: 23836409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Samadi P; Grégoire L; Rouillard C; Bédard PJ; Di Paolo T; Lévesque D
    Ann Neurol; 2006 Feb; 59(2):282-8. PubMed ID: 16437566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Chen L; Togasaki DM; Langston JW; Di Monte DA; Quik M
    Neuroscience; 2005; 132(2):409-20. PubMed ID: 15802193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.
    Zhang D; Mallela A; Sohn D; Carroll FI; Bencherif M; Letchworth S; Quik M
    J Pharmacol Exp Ther; 2013 Oct; 347(1):225-34. PubMed ID: 23902940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P; Grégoire L; Hadj Tahar A; Di Paolo T; Rouillard C; Bédard PJ
    Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.
    Quik M; Mallela A; Chin M; McIntosh JM; Perez XA; Bordia T
    Neurobiol Dis; 2013 Feb; 50():30-41. PubMed ID: 23009753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
    Giorgi M; D'Angelo V; Esposito Z; Nuccetelli V; Sorge R; Martorana A; Stefani A; Bernardi G; Sancesario G
    Eur J Neurosci; 2008 Sep; 28(5):941-50. PubMed ID: 18717735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.
    Iravani MM; Costa S; Al-Bargouthy G; Jackson MJ; Zeng BY; Kuoppamäki M; Obeso JA; Jenner P
    Eur J Neurosci; 2005 Sep; 22(6):1305-18. PubMed ID: 16190886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.